Ostatné · ABT
Abbott Laboratories
Fundamenty firmy Healthcare · Medical Devices · United States
Hodnotenie 0–10, vypočítané z údajov firmy
Analytici 25 hodnotení
silný nákup
- Najnižší cieľ
- 103,00
- Priemerný cieľ
- 120,58
- Najvyšší cieľ
- 135,00
- Potenciál
- +20,6 %
Odhad zisku na akciu (EPS)
| Obdobie | Odhad | Rozpätie | Pred rokom | Rast |
|---|---|---|---|---|
| tento štvrťrok | 1,42 | 1,41–1,44 | 1,30 | +9,2 % |
| budúci štvrťrok | 1,64 | 1,59–1,67 | 1,50 | +9,2 % |
| tento rok | 5,52 | 5,48–5,57 | 5,15 | +7,2 % |
| budúci rok | 6,07 | 5,88–6,20 | 5,52 | +9,9 % |
Odhad tržieb
| Obdobie | Odhad | Pred rokom | Rast |
|---|---|---|---|
| tento štvrťrok | 13,0 mld. | 11,4 mld. | +14,3 % |
| budúci štvrťrok | 13,5 mld. | 11,5 mld. | +18,2 % |
| tento rok | 50,2 mld. | 44,3 mld. | +13,3 % |
| budúci rok | 54,5 mld. | 50,2 mld. | +8,6 % |
Nákupy a predaje manažérov insider
| Kto | Čo | Hodnota | Dátum |
|---|---|---|---|
| Mccoy John A. JrOfficer | predaj | 2 958 | 02.09. |
| Ford Robert B.Chief Executive Officer | uplatnenie opcií | 21,5 mil. | 25.08. |
| Ford Robert B.Chief Executive Officer | predaj | 46,2 mil. | 25.08. |
| Morrone Louis HOfficer | predaj | 642 506 | 11.08. |
| Stratton John G.Director | nákup | 173 640 | 07.05. |
| Starks Daniel JDirector | nákup | 926 537 | 27.04. |
| Kumbier Michelle ADirector | odmena v akciách | – | 24.04. |
| Babineaux Claire FontenotDirector | odmena v akciách | – | 24.04. |
| O Grady Michael GDirector | odmena v akciách | – | 24.04. |
| Blount Sally EDirector | odmena v akciách | – | 24.04. |
| Roman Michael FDirector | odmena v akciách | – | 24.04. |
| Gonzalez Patricia PaolaDirector | odmena v akciách | – | 24.04. |
Kto vlastní akcie
Blackrock Inc.8,82 %
Vanguard Capital Management LLC6,57 %
State Street Corporation4,68 %
Charles Schwab Investment Management, Inc.3,45 %
Vanguard Portfolio Management LLC2,83 %
Geode Capital Management, LLC2,27 %
Capital Research Global Investors2,13 %
Capital International Investors2,00 %
O firme (popis z Yahoo Finance, anglicky)
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Názor AI
Krátke zhodnotenie trendu, správ a blížiacich sa udalostí.
📅 Výsledky hospodárenia: Streda 21. 10. · odhad EPS 1,42
Odporúčania
K tomuto aktívu zatiaľ nemáme odporúčanie.
Predikcie
Žiadne predikcie.
Súvisiace správy
Žiadne správy so značkou ABT.